This inventor holds 2 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent. Top assignees: Cytolynx Therapeutics Hong Kong Limited, Sanyou Biopharmaceuticals Co., Ltd.. Active years: 2025-2026.
Company Filing History:
1 out of 1 
1 out of 1 Years Active: 2025-2026
Title: Guojun Lang: Innovator in Monoclonal Antibody Development
Introduction
Guojun Lang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His innovative work has the potential to impact therapeutic approaches in various medical conditions.
Latest Patents
Guojun Lang holds a patent for a "Humanized Monoclonal Antibody Targeting BCMA and Having Human Monkey Cross-Reactivity." This patent showcases his expertise in creating targeted therapies that can enhance treatment efficacy while minimizing side effects.
Career Highlights
Lang is currently associated with Cytolynx Therapeutics Hong Kong Limited, where he continues to advance his research and development efforts. His work at Cytolynx Therapeutics focuses on innovative solutions in the field of antibody therapies.
Collaborations
He collaborates with notable colleagues, including Ning Li and Guoqing Cao, who contribute to his research endeavors. Their combined expertise fosters a collaborative environment that enhances the potential for groundbreaking discoveries.
Conclusion
Guojun Lang's contributions to monoclonal antibody development exemplify the innovative spirit of modern biotechnology. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.